Steady remission of scleromyxedema 3 years after autologous stem cell transplantation: an in vivo and in vitro study
- 15 July 2006
- journal article
- Published by American Society of Hematology in Blood
- Vol. 108 (2) , 773-774
- https://doi.org/10.1182/blood-2006-01-0186
Abstract
ASCT following treatment with high-dose melphalan alone appeared effective in 3 previous reports,1-3 although in several cases, skin lesions relapsed and had to be retreated with melphalan.Keywords
This publication has 6 references indexed in Scilit:
- Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantationBlood, 2006
- Successful Treatment of Scleromyxedema With Autologous Peripheral Blood Stem Cell TransplantationArchives of Dermatology, 2005
- Mechanisms and effectors of MIF-dependent promotion of tumourigenesisCellular Signalling, 2004
- Identification of copper/zinc superoxide dismutase as a nitric oxide-regulated gene in human (HaCaT) keratinocytes: implications for keratinocyte proliferationBiochemical Journal, 2000
- Profilins as regulators of actin dynamicsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1997
- Lichen Myxedematosus Serum Stimulates Human Skin Fibroblast ProliferationScience, 1978